dimenium 50 mikrograma + 500 mikrograma u jednoj dozi, prašak inhalata, dozirani
elpen pharmaceutical co.inc. (sa), 95, marathonos ave., pikermi, attica, grčka - salmeterolksinafoat flutikazonpropionat - prašak inhalata, dozirani - 50 mikrograma + 500 mikrograma - urbroj: jedna doza praška inhalata sadrži 50 mikrograma salmeterola u obliku salmeterolksinafoata i 500 mikrograma flutikazonpropionata
novapio plus 15 mg/850 mg filmom obložene tablete
novatin limited, 230, second floor, eucharistic congress road, mosta, malta - pioglitazonklorid metforminklorid - filmom obložena tableta - 15 mg + 850 mg - urbroj: jedna tableta sadrži 15 mg pioglitazona (u obliku klorida) i 850 mg metforminklorida
unilat 50 mikrograma/ml kapi za oko, otopina
unimed pharma spol. s r.o., orieskova 11, bratislava, slovačka - latanoprost - kapi za oko, otopina - 50 mikrograma/ml - urbroj: 1 ml otopine sadrži 50 mikrograma latanoprosta
rydapt 25mg kapsula, meka
"novartis pharma services ag" dio stranog druŠtva podgorica - midostaurin - kapsula, meka - 25mg
rydapt 25mg kapsula, meka
"novartis pharma services ag" dio stranog druŠtva podgorica - midostaurin - kapsula, meka - 25mg
seretide inhaler 25 µg/1 doza+ 50 µg/1 doza suspenzija za inhalaciju pod pritiskom
evropa lijek pharma d.o.o. - flutikazon, Салметерол - suspenzija za inhalaciju pod pritiskom - 25 µg/1 doza+ 50 µg/1 doza - 1 doza suspenzije za inhalaciju pod pritiskom sadrži: 25 mcg salmeterola (u obliku salmeterol ksinafoata); 50 mcg flutikazon propionata
seretide inhaler 25 µg/1 doza+ 125 µg/1 doza suspenzija za inhalaciju pod pritiskom
evropa lijek pharma d.o.o. - flutikazon, Салметерол - suspenzija za inhalaciju pod pritiskom - 25 µg/1 doza+ 125 µg/1 doza - 1 doza suspenzije za inhalaciju pod pritiskom sadrži: 25 mcg salmeterola (u obliku salmeterol ksinafoata); 125 mcg flutikazon propionata
seretide inhaler 25 µg/1 doza+ 250 µg/1 doza suspenzija za inhalaciju pod pritiskom
evropa lijek pharma d.o.o. - flutikazon, Салметерол - suspenzija za inhalaciju pod pritiskom - 25 µg/1 doza+ 250 µg/1 doza - 1 doza suspenzije za inhalaciju pod pritiskom sadrži: 25 mcg salmeterola (u obliku salmeterol ksinafoata); 250 mcg flutikazon propionata
rivaroxaban accord
accord healthcare s.l.u. - rivaroksaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotska sredstva - prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 za hemodinamski nestabilne ТЭЛА pacijenata). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 i 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
herzuma 420 mg/1 bočica prašak za koncentrat za rastvor za infuziju
oktal pharma d.o.o. sarajevo - trastuzumab - prašak za koncentrat za rastvor za infuziju - 420 mg/1 bočica - 1 bočica sadrži: 420 mg trastuzumaba